Senior Neuroblastoma Clinical Trials Coordinator
|University of Birmingham Cancer Research Clinical Trials Unit
|£277,410 over 5 years
|Solving Kids’ Cancer UK contribution
|£277,410 over 5 years
With neuroblastoma being considered as a rare disease, a solid infrastructure is essential to ensure that progress in clinical trials is sustained and accelerated and not left behind other areas of cancer research. The Clinical Trials Unit at the University of Birmingham manages coordination of the majority of children’s cancer trials across the UK, also incorporating international collaboration.
Solving Kids’ Cancer UK funds a specific Senior Trials Coordinator for neuroblastoma, which is the first post of this kind dedicated to a specific childhood cancer. Dr Jen Laidler is responsible for all neuroblastoma trials in the portfolio at CRCTU, and monitors progress, implementation and impact of the trials. Having a post that is specifically dedicated to neuroblastoma both increases the unit’s capacity for these trials and allows more focus on efficiency of trial delivery which will bring impact to children more quickly.
Meet Our Senior Clinical Trials Coordinator
After 10 years working commercially making cancer testing kits, Jen wanted a role closer to research and developing cancer treatments. When she took her first job at the CRCTU (Cancer Research Clinical Trials Unit), this didn’t disappoint and she started work on a small innovative trial involving children with neuroblastoma. Like many people, Jen hadn’t heard of neuroblastoma before and was lucky to learn from the teams in the CRCTU and at the hospitals we worked with.
She continued to learn, working on a larger, international trial (BEACON-Neuroblastoma) and met some of the great researchers and consultants working on neuroblastoma treatments around Europe. Since then, she has worked on other trials in other disease areas, but my experience in neuroblastoma in those first years became useful again when she took on the Senior Trials Coordinator position.
Jen is currently working on 5 trials which are recruiting or in follow up and another 2 trials being developed. She looks forward to continually learning, as new developments and ideas are discussed at every meeting, and working with SKC to help educate and accelerate the progress of the trials for children with neuroblastoma.